May 3, 2023
Dr. Schiemann presents at the Biotech Forum on innovative treatments using new classes of antibodies
The Ymmunobio team traveled to London to participate in LSX World Congress on May 3 & 4, 2023. Ymmunobio Chairman of the Board Peter Schiemann, PhD, shared our research into innovative treatments with new classes of antibodies. He was joined by Chief Business Officer Angela S. Gibbs.
We were pleased to participate in LSX World Congress, which is Europe’s largest and most significant Biotech CEO gathering. No other event is exclusively designed to address all the strategic and partnering goals of Europe’s Biotech CEO ecosystem.
Dr. Schiemann discussed our presentation "Innovative Treatments in GI Cancer through New Classes of Antibodies."
LSX World Congress attracts the highest quality speakers from the biggest and best large pharma and life science investment firms. Hear from global BD heads at Pfizer, J&J, Merck KGaA, BMS, Novo Nordisk and top tier investment funds like Blackstone, JP Morgan, Sofinnova and Axa.